Skip to main content Back to Top
Advertisement

7/29/2022

Ioversol Injection

Products Affected - Description

    • Optiray 300 solution for injection, Guerbet, 100 mL bottle, 12 count, NDC 00019-1332-11
    • Optiray 300 solution for injection, Guerbet, 100 mL prefilled syringe, 20 count, NDC 00019-1332-90
    • Optiray 300 solution for injection, Guerbet, 100 mL RFID technology prefilled syringe, NDC 00019-1332-00
    • Optiray 300 solution for injection, Guerbet, 200 mL bottle, 12 count, NDC 00019-1332-21
    • Optiray 300 solution for injection, Guerbet, 50 mL Hand Held prefilled syringe, 20 count, NDC 00019-1332-78
    • Optiray 300 solution for injection, Guerbet, 50 mL vial, 25 count, NDC 00019-1332-06
    • Optiray 300 solution for injection, Guerbet, 500 mL pharmacy bulk pack, multi-dose bottle, 6 count, NDC 00019-1332-61 - discontinued
    • Optiray 320 solution for injection, Guerbet, 100 mL bottle, 12 count, NDC 00019-1323-11
    • Optiray 320 solution for injection, Guerbet, 100 mL prefilled syringe, 20 count, NDC 00019-1323-90
    • Optiray 320 solution for injection, Guerbet, 100 mL RFID technology prefilled syringe, NDC 00019-1323-00
    • Optiray 320 solution for injection, Guerbet, 125 mL prefilled syringe, 20 count, NDC 00019-1323-87
    • Optiray 320 solution for injection, Guerbet, 125 mL RFID technology prefilled syringe, NDC 00019-1323-27
    • Optiray 320 solution for injection, Guerbet, 150 mL bottle, 12 count, NDC 00019-1323-16
    • Optiray 320 solution for injection, Guerbet, 20 mL vial, 25 count, NDC 00019-1323-02
    • Optiray 320 solution for injection, Guerbet, 200 mL bottle, 12 count, NDC 00019-1323-21
    • Optiray 320 solution for injection, Guerbet, 30 mL vial, 25 count, NDC 00019-1323-04 - discontinued
    • Optiray 320 solution for injection, Guerbet, 50 mL Hand Held prefilled syringe, 20 count, NDC 00019-1323-78
    • Optiray 320 solution for injection, Guerbet, 50 mL prefilled syringe, 20 count, NDC 00019-1323-52
    • Optiray 320 solution for injection, Guerbet, 50 mL vial, 25 count, NDC 00019-1323-06
    • Optiray 320 solution for injection, Guerbet, 500 mL pharmacy bulk pack, multi-dose bottle, 6 count, NDC 00019-1323-61 - discontinued
    • Optiray 320 solution for injection, Guerbet, 75 mL prefilled syringe, 20 count, NDC 00019-1323-95
    • Optiray 320 solution for injection, Guerbet, 75 mL RFID technology prefilled syringe, NDC 00019-1323-85
    • Optiray 350 solution for injection, Guerbet, 100 mL bottle, 12 count, NDC 00019-1333-11
    • Optiray 350 solution for injection, Guerbet, 100 mL prefilled syringe, 20 count, NDC 00019-1333-90
    • Optiray 350 solution for injection, Guerbet, 100 mL RFID technology prefilled syringe, NDC 00019-1333-00
    • Optiray 350 solution for injection, Guerbet, 125 mL prefilled syringe, 20 count, NDC 00019-1333-87
    • Optiray 350 solution for injection, Guerbet, 125 mL RFID technology prefilled syringe, NDC 00019-1333-27
    • Optiray 350 solution for injection, Guerbet, 150 mL bottle, 12 count, NDC 00019-1333-16
    • Optiray 350 solution for injection, Guerbet, 200 mL bottle, 12 count, NDC 00019-1333-21
    • Optiray 350 solution for injection, Guerbet, 50 mL Hand Held prefilled syringe, 20 count, NDC 00019-1333-78
    • Optiray 350 solution for injection, Guerbet, 50 mL prefilled syringe, 20 count, NDC 00019-1333-52 - discontinued
    • Optiray 350 solution for injection, Guerbet, 50 mL RFID technology prefilled syringe, NDC 00019-1333-55 - discontinued
    • Optiray 350 solution for injection, Guerbet, 50 mL vial, 25 count, NDC 00019-1333-06
    • Optiray 350 solution for injection, Guerbet, 500 mL pharmacy bulk pack, multi-dose bottle, 6 count, NDC 00019-1333-61 - discontinued
    • Optiray 350 solution for injection, Guerbet, 75 mL prefilled syringe, 20 count, NDC 00019-1333-95

Reason for the Shortage

    • Iohexol (Omnipaque - GE Healthcare) injection is currently in shortage due to the shutdown of a production facility in Shanghai, China during a COVID-19 lockdown. The facility is open again and production is operating at full capacity. As a result of the iohexol shortage, other contrast agents may be affected as organizations seek suitable alternatives.
    • Guerbet states Optiray is on back order due to a shortage of raw material.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Guerbet has Optiray 320 in 50 mL vials, 100 mL bottles, 150 mL bottles, 100 mL RFID syringes, 75 mL syringes, and 100 mL syringes on back order and the company estimates a release date in late-August 2022. Optiray 320 in 200 mL bottles, Optiray 320 in 500 mL bottles, and Optiray 350 in 100 mL bottles are on allocation. Optiray 320 in 125 mL, Optiray 300 in 100 mL syringes, Optiray 350 in 150 mL bottles, and Optiray 350 in 75 mL power syringes are on intermittent back order and the company is releasing supplies as they become available. Optiray 350 in 125 mL RFID syringes, 100 mL syringes, and 125 mL syringes are on back order and the company estimates a release date in mid-August. Optiray 350 in 50 mL bottles are on back order and the company estimates a release date in early-September 2022. Optiray 300 50 mL vials, Optiray 350 in 200 mL bottles are on back order and the company estimates a release date in late-August 2022. All other presentations are on back order and the company cannot estimate a release date.

Alternative Agents & Management

Updated

Updated July 29, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 20, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.